Cytology and Human Papillomavirus Screening Test Results Associated With 2827 Histopathologic Diagnoses of Cervical Intraepithelial Neoplasia 2/3

被引:5
|
作者
Zhao, Chengquan [1 ]
Amin, Milon [1 ]
Weng, Baoying [2 ]
Chen, Xiangbai [2 ]
Kanbour-Shakir, Amal [1 ]
Austin, R. Marshall [1 ]
机构
[1] Univ Pittsburgh, Magee Womens Hosp, Med Ctr, Dept Pathol, Pittsburgh, PA 15213 USA
[2] Conemaugh Hlth Syst, Dept Pathol, Johnstown, PA USA
关键词
LIQUID-BASED CYTOLOGY; FOLLOW-UP FINDINGS; 2006 CONSENSUS GUIDELINES; ATYPICAL SQUAMOUS-CELLS; DISEASE RISK-ASSESSMENT; PAPANICOLAOU TEST; CONVENTIONAL CYTOLOGY; UNDETERMINED SIGNIFICANCE; DNA DETECTION; USEFUL OPTION;
D O I
10.5858/arpa.2012-0307-OA
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-Cervical screening in the United States increasingly involves newer US Food and Drug Administration-approved cytologic methods and adjunctive high-risk human papillomavirus (hrHPV) DNA testing. Objective.-To document cervical screening test performance preceding histopathologic cervical intraepithelial neoplasia (CIN) 2/3 diagnoses. Design.-Preceding screening test results with computer-imaged, liquid-based cytology (LBC) and hrHPV results were analyzed for 2827 patients with histopathologic CIN 2/3 diagnoses. Results.-Of 2827 patients with CIN 2/3 diagnoses, 2074 (73.4%) had system LBC findings within 4 months of CIN 2/3 diagnoses: high-grade squamous intraepithelial lesion (n = 862; 41.6%), low-grade squamous intraepithelial lesion (n = 464; 22.4%), atypical squamous cells of undetermined significance (n = 445; 21.5%), atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (n 288; 13.9%), and atypical glandular cells/adenocarcinoma in situ (n = 15; 0.7%). Of the 2827 patients, 1488 (52.6%) also had earlier system LBC results at more than 4 months to 3 years before CIN 2/3 diagnoses: one or more abnormal LBC results (n 978; 65.7%), one or more negative LBC results (n = 911; 61.2%), both abnormal and negative LBC (n = 401; 26.9%). Of 807 patients with hrHPV cotest results within 4 months of CIN 2/3 diagnoses, 786 (97.4%) had hrHPV(+) results. Of 454 patients who also had earlier hrHPV results at more than 4 months to 3 years before CIN 2/3 diagnoses: 377 (83.0%) had one or more hrHPV(+) result, 110 (24.2%) had one or more hrHPV(-) result, and 33 (7.3%) had both positive and negative HPV results. Conclusion.-Patients with histopathologic CIN 2/3 had recent abnormal LBC results, most often, high-grade squamous intraepithelial lesions. Among cotested patients, 97.4% (786 of 807) tested hrHPV(+). However, a significant number of patients tested during an extended period of several years had earlier negative Papanicolaou or negative HPV test results, suggesting the recent development of some CIN 2/3 lesions and supporting the value of cotesting for enhanced detection of other developing, small, inaccessible, or nondiagnostic precursor lesions.
引用
收藏
页码:942 / 947
页数:6
相关论文
共 50 条
  • [41] Carbon dioxide laser miniconization for treatment of human papillomavirus infection associated with cervical intraepithelial neoplasia
    Bekassy, Z
    Ahlgren, M
    Eriksson, M
    Lindh, E
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1995, 74 (10) : 822 - 826
  • [42] INTRALESIONAL INTERFERON-BETA TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA ASSOCIATED WITH HUMAN PAPILLOMAVIRUS INFECTION
    PENNA, C
    FALLANI, MG
    GORDIGIANI, R
    SONNI, L
    TADDEI, GL
    MARCHIONNI, M
    TUMORI, 1994, 80 (02) : 146 - 150
  • [43] DIFFERENCE IN PREVALENCE OF HUMAN PAPILLOMAVIRUS GENOTYPES IN CYTOMORPHOLOGICALLY NORMAL CERVICAL SMEARS IS ASSOCIATED WITH A HISTORY OF CERVICAL INTRAEPITHELIAL NEOPLASIA
    VANDENBRULE, AJC
    WALBOOMERS, JMM
    DUMAINE, M
    KENEMANS, P
    MEIJER, CJLM
    INTERNATIONAL JOURNAL OF CANCER, 1991, 48 (03) : 404 - 408
  • [44] Utility of human papillomavirus L1 capsid protein and HPV test as prognostic markers for cervical intraepithelial neoplasia 2+in women with persistent ASCUS/LSIL cervical cytology
    Ki, Eun Young
    Park, Jong Sup
    Lee, Ahwon
    Kim, Tae Jung
    Jin, Hyun Tak
    Seo, Yong Bok
    Gen, Yuki
    Park, Mi Young
    Lee, Sung Jong
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2019, 16 (08): : 1096 - 1101
  • [45] Histopathologic extent of cervical intraepithelial neoplasia 3 lesions correlates with the number of abnormal cells in the preceding FIGSIL thinprep cytology
    Khayyata, SH
    Christensen, C
    Kmak, D
    Husain, M
    LABORATORY INVESTIGATION, 2005, 85 : 66A - 66A
  • [46] Histopathologic extent of cervical intraepithelial neoplasia 3 lesions correlates with the number of abnormal cells in the preceding HGSIL ThinPrep cytology
    Khayyata, SH
    Christensen, C
    Kmak, DD
    Husain, M
    MODERN PATHOLOGY, 2005, 18 : 66A - 66A
  • [47] Low-Risk Human Papillomavirus Types in Cervical Intraepithelial Neoplasia 2-3 and in Invasive Cervical Cancer Patients
    Siegler, Efraim
    Reichman, Yael
    Kugelman, Nir
    Mackuli, Lena
    Lavie, Ofer
    Ostrovsky, Ludmila
    Shaked-Mishan, Pninint
    Segev, Yakir
    JOURNAL OF LOWER GENITAL TRACT DISEASE, 2019, 23 (04) : 248 - 252
  • [48] Human Papillomavirus Type Distribution in Cervical Intraepithelial Neoplasia Grade 2/3 and Cervical Cancer in Portugal A CLEOPATRE II Study
    Pista, Angela
    de Oliveira, Carlos Freire
    Lopes, Carlos
    Cunha, Maria Joao
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (03) : 500 - 506
  • [49] Cytology and High-Risk Human Papillomavirus Test for Cervical Cancer Screening Assessment
    Stuebs, Frederik A.
    Koch, Martin C.
    Dietl, Anna K.
    Adler, Werner
    Geppert, Carol
    Hartmann, Arndt
    Knoell, Antje
    Beckmann, Matthias W.
    Mehlhorn, Grit
    Schulmeyer, Carla E.
    Gass, Paul
    DIAGNOSTICS, 2022, 12 (07)
  • [50] Association of human papillomavirus type 31 variants with risk of cervical intraepithelial neoplasia grades 2-3
    Xi, Long Fu
    Schiffman, Mark
    Koutsky, Laura A.
    Hulbert, Ayaka
    Lee, Shu-Kuang
    DeFilippis, Victor
    Shen, Zhenping
    Kiviat, Nancy B.
    INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (10) : 2300 - 2307